TRDA
Entrada Therapeutics Inc

188
Mkt Cap
$386.4M
Volume
246,925.00
52W High
$21.79
52W Low
$4.93
PE Ratio
-3.95
TRDA Fundamentals
Price
$9.89
Prev Close
$10.11
Open
$10.13
50D MA
$6.72
Beta
1.20
Avg. Volume
181,412.83
EPS (Annual)
$1.68
P/B
1.11
Rev/Employee
$1.15M
Loading...
Loading...
News
all
press releases
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five research firms that are currently covering the firm...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Ventures L.P. 5Am Sells 200,000 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Ventures L.P. 5Am sold 200,000 shares of Entrada Therapeutics stock in a transaction that occurred on Friday, November...
MarketBeat·5d ago
News Placeholder
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells 200,000 Shares of Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Kush Parmar sold 200,000 shares of the company's stock in a transaction on Friday, November 14th. The stock was sold at an average...
MarketBeat·6d ago
News Placeholder
Bros. Advisors Lp Baker Acquires 46,434 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Bros. Advisors Lp Baker purchased 46,434 shares of Entrada Therapeutics stock in a transaction dated Tuesday, November...
MarketBeat·11d ago
News Placeholder
Insider Buying: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Buys 30,874 Shares of Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Bros. Advisors Lp Baker acquired 30,874 shares of the firm's stock in a transaction dated Monday, November 10th. The stock...
MarketBeat·11d ago
News Placeholder
Bros. Advisors Lp Baker Acquires 100,736 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Bros. Advisors Lp Baker bought 100,736 shares of the company's stock in a transaction that occurred on Wednesday, November...
MarketBeat·11d ago
News Placeholder
Insider Buying: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Purchases 46,434 Shares of Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Bros. Advisors Lp Baker acquired 46,434 shares of the stock in a transaction dated Tuesday, November 11th. The stock was...
MarketBeat·12d ago
News Placeholder
Entrada Therapeutics (NASDAQ:TRDA) Posts Earnings Results, Misses Expectations By $0.02 EPS
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus...
MarketBeat·17d ago
News Placeholder
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of -1.92% and -69.94%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·19d ago
News Placeholder
Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates
Bristol Myers (BMY) delivered earnings and revenue surprises of +10.14% and +3.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·26d ago

Latest TRDA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.